FCH
NKTR icon

Freestone Capital Holdings’s Nektar Therapeutics NKTR Stock Holding History

Freestone Capital Holdings’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,333
Closed -$11.3K – 458
2023
Q4 		$11.3K Hold
1,333
– – ﹤0.01% 399
2023
Q3 		$11.9K Buy
+1,333
New +$12.8K ﹤0.01% 374

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Freestone Capital Holdings's NKTR Position: Q1 2024 in Review

Freestone Capital Holdings sold out of Nektar Therapeutics (NKTR) in Q1 2024, closing a stake of 1,333 shares — an estimated $11.3K sold.

Freestone Capital Holdings first reported a position in NKTR in Q3 2023 and held it in 2 quarters. The position peaked at $11.9K in Q3 2023. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

  • Freestone Capital Holdings reported no remaining Nektar Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Freestone Capital Holdings sold 1,333 Nektar Therapeutics shares in Q1 2024, an estimated $11.3K.
  • Freestone Capital Holdings first reported a position in Nektar Therapeutics in Q3 2023 and held it in 2 quarters.
  • Freestone Capital Holdings's Nektar Therapeutics position peaked at $11.9K in Q3 2023.
  • 124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on Freestone Capital Holdings's 13F filing for Q1 2024, filed 14 May 2024.